Video
Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs
Author(s):
Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.
Daneng Li, MD, medical oncologist, assistant professor, Department of Medical Oncology & Therapeutics Research, co-director, Neuroendocrine Tumor Program, City of Hope, discusses the interim analysis results of a phase 1 trial (NCT02549937) evaluating surufatinib in United States patients with neuroendocrine tumors (NETs).
Interim findings from a phase 1 dose-escalation and dose-expansion study, which were presented during the 2021 NANETS Symposium, demonstrated antitumor activity with surufatinib in heavily pretreated, United States–based patients with progressive NETs. Moreover, the data were consistent with 2 completed phase 3 studies that were performed with surufatinib in Chinese patients with NETs.
In the phase 1 trial, surufatinib elicited an objective response rate of 6.3% in 16 patients with extrapancreatic NETs and 18.8% in 16 patients with pancreatic NETs. The disease control rates were 93.8% and 87.5%, respectively.
The median progression-free survival (PFS) was 11.5 months in patients with extrapancreatic NETs and 15.2 months in patients with pancreatic NETs. The 11-month PFS rates were 51.1% and 57.4%, respectively, Li concludes.
